H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Alimera (ALIM) today and set a price target of $2.75. The company’s shares closed yesterday at $1.16, close to its 52-week high of $1.21.
Selvaraju wrote:
“Our price target is derived from an estimated market value of the firm at $190M. This includes a discounted cash flow based enterprise value of the firm at $261M, excluding $40M debt and $30M preferred stock. The DCF analysis utilizes a 15% discount rate and a 2% terminal growth rate.”
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -10.1% and a 31.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Alimera has an analyst consensus of Moderate Buy, with a price target consensus of $2.75.
See today’s analyst top recommended stocks >>
Alimera’s market cap is currently $81.29M and has a P/E ratio of 5.64. The company has a Price to Book ratio of -2.94.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion.
